1402924-31-5
1402924-31-5
Chemical Structure
Valganciclovir-d5 TFA
- CAS No.: 1402924-31-5
- Formula:C16H18D5F3N6O7
- Molecular Weight:473.42
IUPAC Name: 2-((2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)methoxy)-3-hydroxypropyl-1,1,2,3,3-d5 L-valinate 2,2,2-trifluoroacetate
InChIKey: WUNQNEOHCSWAGB-YFXYRKRRSA-N
SMILES: OC(C(F)(F)F)=O.CC(C)[C@H](N)C(OC([2H])([2H])C(C([2H])([2H])O)([2H])OCN1C2=C(C(N=C(N2)N)=O)N=C1)=O
Biological Activity: Valganciclovir-d5 (TFA) is the deuterium labeled Valganciclovir TFA[1]. Valganciclovir, the L-valyl ester of ganciclovir, is actually a proagent for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections[2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Valganciclovir-d5 TFA | Valganciclovir-d5 (TFA) is the deuterium labeled Valganciclovir TFA. Valganciclovir, the L-valyl ester of ganciclovir, is actually a proagent for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valganciclovir | Valganciclovir is an orally active antiviral agent. Valganciclovir can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir can be used for the research of Cytomegalovirus. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9. [Content Brief]
- [3]. Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun14(3):259-67. [Content Brief]
- [4]. O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15111(4):1816-9. [Content Brief]
